Products
Tools
Education
$14.05
$13.65
$16.15
$5.96
$687.5M
78.39%
This is a preview of the full version of Prosperse
Mineralys Therapeutics, Inc. (MLYS) released its Q2 2024 financial results, which missed analyst consensus estimates, causing a sharp drop in the company's stock price. Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mineralys investors.
Bronstein, Gewirtz & Grossman, Llc
Sep 16, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024